Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Profit After Tax (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Profit After Tax data on record, last reported at -$16.4 million in Q1 2026.

  • On a quarterly basis, Profit After Tax fell 19.75% to -$16.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$51.0 million, a 39.43% decrease, with the full-year FY2025 number at -$48.3 million, down 75.36% from a year prior.
  • Profit After Tax reached -$16.4 million in Q1 2026 per IKT's latest filing, down from -$12.7 million in the prior quarter.
  • Over the last five years, Profit After Tax for IKT hit a ceiling of -$4.2 million in Q4 2023 and a floor of -$16.4 million in Q1 2026.
  • A 5-year average of -$7.6 million and a median of -$5.0 million in 2024 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: increased 15.13% in 2022, then plummeted 194.19% in 2025.
  • Tracing IKT's Profit After Tax over 5 years: stood at -$4.3 million in 2022, then increased by 2.36% to -$4.2 million in 2023, then crashed by 190.4% to -$12.1 million in 2024, then fell by 4.96% to -$12.7 million in 2025, then dropped by 28.63% to -$16.4 million in 2026.
  • Business Quant data shows Profit After Tax for IKT at -$16.4 million in Q1 2026, -$12.7 million in Q4 2025, and -$11.9 million in Q3 2025.